Bempikibart Shows Promise for Hair Loss | Business and Finance News

Q32 Bio’s stock soars after breakthrough trial data for its new hair loss drug, bempikibart, showing a 35% average reduction in scalp hair loss severity over 36 weeks—with no serious side effects. The treatment, targeting alopecia areata, could help hundreds of thousands in the U.S., and analysts are already boosting price targets, signaling strong investor confidence in the biotech’s future.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/0f8302c1e01f3e52